TITLE

Antiviral Medications Not Associated with Birth Defects

PUB. DATE
October 2010
SOURCE
Travel Medicine Advisor;Oct2010 Supplement, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents the "Pharmacology Watch" journal, which discusses antiviral drugs, birth defects, bisphosphonates and esophageal cancer in the U.S. It outlines the use of oral antivirals acyclovir, valacyclovir and famciclovir to treat young women with herpes infections. Also presented is the move of Food and Drug Administration to withdraw approval of the drug midodrine hydrochloride.
ACCESSION #
53918885

 

Related Articles

  • Drugs to treat the flu. Napoli, Maryann // Center for Medical Consumers;Jan2012, p1 

    The article reports that Swiss pharmaceutical firm Roche allegedly withheld some clinical studies about safety and effectiveness of its anti-influenza drug Tamiflu, according to the Cochrane Collaboration. Cochrane drug reviewer Tom Jefferson and colleagues discovered that while Tamiflu can...

  • Cancer drug could affect dental work. Schlossberg, Matt // Dental Practice Report;Jun2005, Vol. 13 Issue 5, p54 

    Reports on the recommendation of the U.S. Food and Drug Administration and Novartis Pharmaceuticals Corp. that cancer patients avoid invasive dental procedures while undergoing intravenous therapy using the bisphosphonates pamidronate disodium or zoledronic acid. Potential links between the...

  • FDA Warnings Dominate Pharmaceutical News. Elliott, William T. // Primary Care Reports;Jan2008, Vol. 14 Issue 1, p1 

    The article reports on the banning of erythropoiesis-stimulating agents (ESA) by the Food & Drug Administration (FDA) in the U.S. The warnings are the drive for safety of the FDA to regulate existing drugs after being approved for marketing. Studies show that ESA promote tumor growth and...

  • Zanamivir approved to treat influenza. Maudlin, Robert K. // Modern Medicine;Sep99, Vol. 67 Issue 9, p56 

    Reports the approval of Zanamivir drug by the United States Food and Drugs Administration for the treatment of acute illness to influenza virus A and B. Administration and dosage of the medicine to patients; Effectiveness; Side effects.

  • FDA Actions.  // Clinical Cardiology Alert;Dec2009 Pharmacology Watch, p2 

    The article focuses on the approval by the U.S. Food and Drug Administration of the emergency use of antiviral peramivir to treat 2009 H1N1 influenza in hospitalized patients. The author notes that the drug is not yet approved for use in the country but was authorized due to a request from...

  • Dolutegravir Tablets (Tivicay®). Elliott, William T.; Chan, James // Internal Medicine Alert;9/15/2013, Vol. 35 Issue 17, p133 

    In this article, the author discusses dosage, potential advantages and disadvantages and clinical implications of the Dolutegravir Tablets.

  • FDA draft guidance on developing direct-acting antiviral drugs for treatment of chronic HCV infection.  // CenterWatch Monthly;Jan2014, Vol. 21 Issue 1, p6 

    The article reports on the draft guidance issued by the U.S. Food & Drug Administration (FDA) on developing direct-acting antiviral drugs (DAA) for treatment of chronic Hepatitis C virus (HCV) infection. The purpose of this guidance is to assist sponsors in all phases of development of DAA for...

  • Gene-Eden-VIR Decreased Physical and Mental Fatigue in a Post Marketing Clinical Study That Followed FDA Guidelines; Results Support Microcompetition Theory. Polansky, Hanan; Itzkovitz, Edan // Pharmacology & Pharmacy;Mar2014, Vol. 5 Issue 3, p280 

    Objective: The Microcompetition with Foreign DNA theory, proposed by Hanan Polansky in 2003, describes how latent viruses can cause chronic conditions, including fatigue. The Gene-Eden-VIR formula was designed to target latent viruses. Therefore, the theory predicts that treatment with...

  • Sofosbuvir: First Global Approval. Keating, Gillian; Vaidya, Asha // Drugs;Feb2014, Vol. 74 Issue 2, p273 

    Sofosbuvir (Solvadiâ„¢), a nucleotide analogue hepatitis C virus NS5B polymerase inhibitor, is under development with Gilead Sciences for the once-daily, oral treatment of chronic hepatitis C. Oral sofosbuvir has been approved in the US for the treatment of chronic hepatitis C as a component...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics